Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2.

Abstract

PURPOSE This phase II study (S0341) evaluated the efficacy and tolerability of single-agent erlotinib in unselected chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) of 2. Exploratory analyses of a number of biomarkers relating to epidermal growth factor receptor pathway activation were also performed. PATIENTS AND METHODS Patients with stage IIIB (pleural effusion) or stage IV NSCLC with a PS of 2 and no prior chemotherapy or biologic treatment for NSCLC received erlotinib 150 mg daily. RESULTS A total of 81 patients entered the study; 76 were assessable. One complete and 5 partial responses were noted for an overall response rate of 8% (95% CI 3%-16%). Stable disease (SD) was seen in 26 patients (34%) resulting in a disease control rate (DCR = CR/PR/SD) of 42%. Progression free and median survival were 2.1 months (95% CI 1.5-3.1) and 5 months (95% CI 3.6-7.2), respectively. One-year survival was 24% (95% CI 15%-34%). Although treatment was generally well tolerated, grade 3 to 4 toxicity was reported in 30 patients (40%), including fatigue (16%), rash (9%), diarrhea (7%), and anorexia (7%). There was one possible treatment related death (pneumonitis). CONCLUSIONS In chemotherapy-naive patients with advanced NSCLC and a PS of 2, single agent erlotinib resulted in an acceptable but significant level of treatment-related side effects. With an overall DCR of 42% and median survival of 5 months, results are comparable to those achieved with chemotherapy in this population. Development of an epidermal growth factor receptor-directed biomarker selection strategy may optimize use of erlotinib in PS 2 patients.

DOI: 10.1097/JTO.0b013e318183aa1f

3 Figures and Tables

Statistics

0100200200920102011201220132014201520162017
Citations per Year

283 Citations

Semantic Scholar estimates that this publication has 283 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Hesketh2008SouthwestOG, title={Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2.}, author={Paul Joseph Hesketh and Kari L Chansky and Antoinette J. Wozniak and Fred R Hirsch and Anna Spreafico and James E. Moon and Philip C. Mack and Benjamin T. Marchello and Wilbur A . Franklin and John Crowley and David R . Gandara}, journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer}, year={2008}, volume={3 9}, pages={1026-31} }